Kamila Wojas-Krawczyk

17PUBLICATIONS
29CO-AUTHORS
Molecular targetsImmunogenetics (incl. genetic immunology)Cancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classifiedTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jan 03, 2026
When genetics meets immunology: the assessment of genetic and immunological backgrounds in advanced NSCLC patients treated with immunotherapy - preliminary study.

Natalia Krzyżanowska, Marcin Nicoś, Kamila Wojas-Krawczyk

|Dec 30, 2025
MTAP Deletion as a Therapeutic Vulnerability in Cancer: From Molecular Mechanism to Clinical Targeting.

Paweł Krawczyk, Kamila Wojas-Krawczyk

|Dec 25, 2025
Immune-Related Adverse Events of Checkpoint Inhibitors and Human Leukocyte Antigen System: A Review.

Kamil Kośmider, Agata Kozakiewicz, Paweł Krawczyk

|Apr 14, 2025
Effectiveness of First-Line Treatment with Anaplastic Lymphoma Kinase and ROS1 Protoncogene Inhibitors in Non-Small Cell Lung Cancer Patients-Real-World Evidence of Two Polish Cancer Centers.

Michał Gil, Kinga Winiarczyk, Paweł Krawczyk

|Jan 20, 2025
Emerging insights into STK11, KEAP1 and KRAS mutations: implications for immunotherapy in patients with advanced non-small cell lung cancer.

Magdalena Knetki-Wróblewska, Kamila Wojas-Krawczyk, Paweł Krawczyk

|Jul 14, 2023
Double Guard Efficiency and Safety-Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients.

Ewa Kalinka, Kamila Wojas-Krawczyk, Paweł Krawczyk

Pageof 3

Frequent Collaborators

4 joint publications

Tomasz Kucharczyk

4 joint publications

Paweł Krawczyk

3 joint publications

Michał Gil

3 joint publications

Janusz Milanowski